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A B S T R A C T
Introduction: Congenital hearing loss is associated with cardiac rhythm disturbances namely long Q-T syndrome.
This study was designed to investigate the effect of anti-emetic doses of ondansetron and dexamethasone on ECG
recordings in children undergoing cochlear implant surgery.
Methods: Sixty-three pediatric patients scheduled for elective cochlear implantation were enrolled in the study.
Two patients were excluded as their baseline ECG showed long QT syndrome. Anesthesia was induced with
fentanyl, propofol and atracurium and maintained with propofol. Dexamethasone 0.1 mg.kg−1or ondansetron
0.2 mg.kg−1was randomly administered for the participants approximately 30 min before the end of surgery.
ECG recording was performed 15 min after induction of anesthesia and 15 min after dexamethasone/ondan-
setron administration. RR interval, QRS duration, QT interval, and Tp-e interval were measured by a blinded
cardiologist.
Results: Ondansetron resulted in no significant changes in RR, JTc and QTc intervals; while prolongedTp-e in-
terval. Multivariable logistic regression analysis showed that use of ondansetron was an independent predictor of
QTc prolongation after adjustment for age, gender and baseline QTc (OR = 17.94, CI 95% 1.97–168.70,
p = 0.011). The incidence of postoperative retching/vomiting in ondansetron group was significantly lower
than dexamethasone group. (3.2% vs. 26.7%, p = 0.011).
Conclusion: The risk of arrhythmias with the use of ondansetron in otherwise healthy candidates of cochlear
implant is very low. However, the drug may induce significant changes in ECG parameters. The clinical sig-
nificance of these changes in patients with cardiac conduction abnormalities should be investigated in further
studies.
1. Introduction
Nowadays, many children are admitted for cochlear implant for
early onset inherited hearing loss [1]. One common complication of the
surgery is post-operative nausea and vomiting (PONV) due to manip-
ulation of the inner ear [1–3]. Common groups of antiemetic dugs in-
cluding dopamine receptor antagonists like droperidol, 5HT3R receptor
antagonists like ondansetron and corticosteroids such as dex-
amethasone may provoke the risk of QT prolongation [4,5]. Long QT
interval is partly because of delayed repolarization of the ventricles that
might lead to arrhythmias such as ventricular tachycardia and torsade
de point [6]. The frequency of long QT syndrome (LQTS) in children
among all patients with congenital deafness is thought to be less than 1
in 50,000. However, patients with congenital sensorineural hearing loss
including Jervell and Lange-Nielsen syndrome are already at increased
risk of sudden cardiac death, even being asymptomatic before [7]. This
necessitates ECG screening and a safe plan of anesthesia considering the
potential for arrhythmogenicity of medications.
New electrical markers, including the interval between the peak and
the end of the T wave (T p-e), stand out due to their ability to suggest
the presence of refractory transmural dispersion, with potential appli-
cation in the stratification of arrhythmogenic risk in different popula-
tions [8–12]. The JT interval is more effective for ventricle repolar-
ization as it has been described more specific for arrhythmia prognosis
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in patients with QRS duration more than 120 ms. It has been also de-
scribed as an independent risk factor for sudden death in patients with
coronary artery disease. However, little is known about the behavior of
these markers in children undergoing anesthesia. This study was con-
ducted to investigate the effect of anti-emetic doses of ondansetron and




Sixty-one pediatric patients scheduled for elective one-sided co-
chlear implantation were enrolled in the study. The diagnosis of deaf-
ness in pre-lingual cases was confirmed with otoacoustic emission
(OAE) and auditory brainstem response (ABR) tests. In post-lingual
subjects, pure tone audiometry was done. For more evaluation temporal
bone CT scan or MRI was done according to our cochlear implant center
policy. The exclusion criteria were children with known cardiac disease
including arrhythmias or conduction abnormalities, taking medicine
known to induce conduction abnormalities, thyroid disease and ab-
normal serum electrolyte measurements. With the approval of the
medical ethics committee of the university, the clinical trial was re-
gistered as IRCT number of IRCT2016122031487N1.
2.2. Protocol of anesthesia
The children were conducted to the waiting room 30 min before the
surgery. They were premedicated with oral midazolam 0.4 mg kg−1 in
20 ml clear apple juice. After approximately 20 min a trace of ECG was
taken to rule out long Q-T syndrome or other conduction abnormalities.
For those with insufficient sedation to obtain ECG an intravenous access
was applied and an additional dose of midazolam 0.05 mg.kg−1was
administered. Then the children were transported to the operating
room. Children who required inhalation anesthesia to apply IV access
and those who were not satisfactorily immobile to obtain ECG were
excluded from study.
After standard monitoring, anesthesia was induced with fentany-
l2ug.kg−1, propofol 2 mg.kg−1and atracurium 0.5 mg.kg−1and main-
tained with propofol. Intubation was performed by an expert anesthe-
siologist for minimum sympathetic stimulation. Mechanical ventilation
was conveyed with 50% oxygen/air to maintain normocapnia.
Percutaneous temperature monitoring was applied intraoperatively.
Forced warmed air with blanket was used to maintain normothermia.
2.3. Study protocol
Twelve lead ECG was taken fifteen minutes after induction of an-
esthesia. During this period the patients were only positioned, draped,
and nerve monitoring was applied to minimize painful stimuli. The ECG
recordings were obtained at the supine position with a paper speed of
50 mm/s and voltage of 10 mm/mV. Dexamethasone 0.1 mg.kg−1or
ondansetron 0.2 mg.kg−1was randomly administered for the partici-
pants 30 min before the end of surgery. The randomization was con-
ducted by a research assistant not involved in the study using computer
generated random numbers which were allocated in sealed envelopes.
The drugs were prepared in a 5 ml syringes diluted with normal saline.
The second ECG was performed 15 min after the administration of
dexamethasone/ondansetron. The occurrence of vomiting or retching
of children at the recovery was also recorded by a blinded observer.
Vomiting was objectively recorded but we could not find a validated
nausea rating scale for very young children. Thus, we defined retching
subjectively as facial expressions of furrowed brow, sweat and open
mouth with head and neck movements usually seen before vomiting.
These facial expressions have been validated earlier for older children.
2.4. Electrocardiography measurements
RR interval, QRS duration, QT interval, and Tp-e interval were
measured manually. Tp-e/QT ratio and Tp-e/QTc ratio were calculated
from these measurements. QT interval was defined as the time from the
onset of the QRS complex to the end of the T wave. QTc interval was
calculated by using the Bazett's formula (QT/√RR). QTc prolongation
was defined as ≥ 470 ms for boys and ≥480 ms for girls. Clinically
significant QTc prolongation was defined as QT interval more than
500 ms or 60 ms increase in QTc from baseline [13]. The JTc has been
proposed as a more appropriate measure of ventricular repolarization
than QTc when QRS duration is ≥ 120 ms.
Tp-e interval was measured from the peak of T wave to the end of T
wave. The end of the T wave was defined as intersection of tangent to
the down slope of T wave and isoelectric line. When the U wave is
present T wave end was defined as the nadir between the T wave and U
wave. The Tp-e interval was also expressed as a ratio to the duration of
QT ([TpTe/QT] × 100%). Measurements of the Tp-e interval were
performed in leads V2 and V5. The mean value of the measurements
was used in the analysis. All measurements were performed by a
blinded cardiologist.
2.5. Statistical analyses
Statistical analyses were performed with SPSS version 18 for win-
dows (SPSS Inc., Chicago, IL, USA). Data were expressed as frequency
(%), mean ± SD or Median (interquartile ranges). Comparison of
variables between ondansetron and dexamethasone groups was done
using independent T test for parametric and Mann-Withney U for
nonparametric ones. Paired t-test was used for within group comparison
of ECG parameters. We used multivariable logistic regression to assess
the association between drugs used and the occurrence of QTc ex-
ceeding 500 ms. Age and sex of participants were considered as po-




Seventy-two pediatric patients with the average age of 3 years old
were included. Of those, nine patients were excluded because of in-
sufficient sedation to obtain baseline ECG or inability to apply IV access
without inhalation anesthesia. Two other participants were excluded as
their baseline ECG showed QT interval more than 500 ms. Thirty one
patients from the ondansetron group and 30 patients in the dex-
amethasone group included in analyses. The consort flow diagram has
been provided Fig. 1. The median (range) age of patients in the on-
dansetron and in dexamethasone groups were comparable (38 (14–207)
vs. 40 (21–150) months, p = 0.92). Sex distribution was comparable as
well (male sex 67% in the ondansetron group versus 43% in the dex-
amethasone group, p = 0.05). The duration of anesthesia in ondanse-
tron group was 91 ± 14 min and in dexamethasone group
84 ± 13 min (p = 0.3). Analyses of ECG parameters before antiemetic
treatment showed similar results in two groups (Table 1, p > 0.05).
3.2. Within group comparisons
Table 1 shows ECG parameters before and after antiemetic treat-
ments. In ondansetron group, there was no significant changes re-
garding heart rate, JTc and QTc intervals; while Tp-e interval increased
by 10 ms on average following drug administration (p = 0.008). These
indices showed no significant change after dexamethasone adminis-
tration (Table 1). Seven patients in the ondansetron group and five
patients in the dexamethasone group showed significant increase in
QTc; defined as QT interval more than 500 ms or 60 ms increase in QTc




We used multivariable logistic regression to assess the association
between drugs used and the fraction of postoperative QTc exceeding
500 ms. Analysis showed that the choice of anti-emetic medication is
not an independent predictor of QTc>500 ms.(OR = 4.89, 95%
CI = 0.455–52.73, p = 0.19). However, when QTc prolongation was
defined as> 470 ms for men and>480 ms for women, administration
of ondansetron was an independent predictor of QTc prolongation after
adjustment for age, gender and baseline QTc (OR = 17.94, CI 95%
1.97–168.70, p = 0.011).
No clinically significant arrhythmias were reported in either group.
The incidence of PONV in the ondansetron group was significantly less
than the dexamethasone group (3.2% vs. 26.7%, p = 0.011).
4. Discussion
We encounter a triangle to be broken. Candidates of cochlear im-
plant may suffer from prolonged QT interval [14], they are prone to
PONV [1], and many antiemetics are known to prolong QT interval
[12,15].The results of this study showed minor changes in JTc, JT and
QTc intervals, but only Tp-e as a predictor of torsadogenicity was sig-
nificantly increased after ondansetron administration. Nevertheless,
ondansetron provided better protection against PONV without produ-
cing clinically significant arrhythmias.
Serotonin receptors on the gastrointestinal tract, postrema, and
nucleus solitarius are responsible for nausea and vomiting. Blockade of
these receptors can reduce the incidence of nausea and vomiting.
Ondansetron is a well-known 5HT receptor antagonist which is known
for its anti-emetic properties. It blocks the human ether-a-go-go related
gene (hERG) potassium channels and increases the action potential thus
may prolong QT interval. Dexamethasone expresses its antiemetic
properties with the mechanism of prostaglandin synthesis inhibitor.
Increasing the permeability of the blood brain barrier may also con-
tribute to its antiemetic properties [16–19]. Earlier reports have sug-
gested that dexamethasone may suppresses long QT phenotype [20].
The possible explanation might be the potential of shortening the
Fig. 1. Consort Flow Diagram
Table 1








Ondansetron (n = 31) Heart
rate
110 (27) 115 (36) 0.37
QTc (ms) 423 (40) 438 (67) 0.24
JTc (ms) 327 (37) 342 (51) 0.22
Tp-e (ms) 78 (16) 88 (20) 0.008
TpTe/
QTc





113 (25) 113 (40) 0.96
QTc (ms) 424 (40) 409 (86) 0.37
JTc (ms) 325 (31) 324 (69) 0.93
Tp-e (ms) 80 (17) 79 (16) 0.66
TpTe/
QTc
0.19 (0.04) 0.22 (0.15) 0.23
Data presented as mean (SD).
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ventricle action potential that has been addressed in animal models.
Taken together, dexamethasone seems to be safe in candidates of co-
chlear implant. Its efficacy is the question to be answered.
Most of earlier studies have reported that ondansetron prolongs QT
interval. It seems that this effect is dose-dependent [5,8,21], more
common in females [6] and occurs about 15 min after drug adminis-
tration [10]. However, reports of arrhythmias are rare [22] and usually
limited to those patients with history of severe cardiac disease [7]. Few
studies have measured Tp-e interval [4,5]. This interval indicates
transmural dispersion of repolarization. Similar to our findings, pro-
longed Tp-e interval as a consequence of ondansetron administration
was not associated with torsadogenicity or any clinically significant
arrhythmias.
4.1. Study limitations
We excluded the patients with known cardiac rhythm disturbances.
Thus, generalization of findings to this subgroup of patients is difficult.
Another limitation of this study is that the half-life of ondansetron is
5–7 h and we did not evaluate the ECG recordings in this period of time.
We could not find a validated scale to evaluate the severity of nausea in
children with average age of three years. Thus, the reported incidence
of retching/vomiting can roughly estimate this secondary outcome of
the study.
4.2. Conclusion
Ondansetron more effectively prevents PONV and the risk of its
arrhythmogenecity in otherwise healthy candidates of cochlear implant
is very low. Thus, it seems to be a better choice than dexamethasone in
patients with QTc< 470 ms. The clinical significance of prolonged Tp-e
interval and arrhythmogenecity of ondansetron in patients with cardiac
conduction abnormalities should be investigated in further studies.
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